2020
DOI: 10.5489/cuaj.6644
|View full text |Cite
|
Sign up to set email alerts
|

Triamcinolone acetonide injections for the treatment of recalcitrant post-radical prostatectomy vesicourethral anastomotic stenosis: A retrospective look at efficacy and safety

Abstract: Introduction: We aimed to evaluate the success of bladder neck injections of triamcinolone at the time of transurethral bladder neck incision (BNI) for prevention of recurrent vesicourethral anastomotic stenosis (VUAS) following prostate cancer treatment. Methods: This is a retrospective cohort study examining patients with recurrent VUAS post-RP ± radiation treated with triamcinolone injections at the time of BNI. VUAS was diagnosed by symptoms followed by cystoscopy or urethrography. The outpatient pro… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
5
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 23 publications
0
5
0
Order By: Relevance
“…The risk of bias assessment was unfavourable for a large majority of studies regarding the measurement of the condition (utilisation of valid method, measurement in a standard, reliable way; Fig. 3 [1,19,27–64]).…”
Section: Resultsmentioning
confidence: 99%
“…The risk of bias assessment was unfavourable for a large majority of studies regarding the measurement of the condition (utilisation of valid method, measurement in a standard, reliable way; Fig. 3 [1,19,27–64]).…”
Section: Resultsmentioning
confidence: 99%
“…The PRISMA guideline was implemented in the study selection. Several studies were excluded due to several reasons, including inappropriate study design [ [11] , [12] , [13] , [14] ], inappropriate comparison [ [15] , [16] , [17] , [18] ] [ [15] , [16] , [17] , [18] ] [ [15] , [16] , [17] , [18] ], observational studies [ 16 , [19] , [20] , [21] ] and an abstract-only articles [ 22 ].…”
Section: Resultsmentioning
confidence: 99%
“…Its first-time success rate ranges between 70% and 85%. [55][56][57][58][59] MMC gives a first-time success rate between 45% and 79%. [48][49][50][51][52][53][54] An anti-fibrinogenic DNA alkylating agent, it prevents DNA replication and therefore cell growth.…”
Section: Injectables (Scar Modulators)mentioning
confidence: 99%